While switching from semaglutide (a GLP-1 agonist) to tirzepatide (a GIP/GLP-1 co-agonist) worsened symptoms, including nausea and epigastric pain, ultimately leading to acute duodenal ulcer perforation, exact contributing factors are unclear. This evidence concerns the gene GIP and duodenal ulcer.